T-cell Receptors are the defining feature of T-cellsTCR Technology
Unique TCRs are created each time a new T-cell is produced within the body, which allows T-cells to recognise the massive amount of potential HLA-displayed antigens The production of many millions of new T-cells occurs each day within individuals, and their TCRs are intricately selected against the HLA-antigen repertoire of that individual. This makes finding TCRs that are suitable for targeting antigens for an individual a challenging process, which requires many steps of selection, validation and characterisation to ensure safety and efficacy of those TCRs when deployed in a therapeutic context.
Anocca has created a range of proprietary genetic and cellular tools to identify, characterise and engineer TCRs in an industrialised process. This is based on sophisticated automated TCR gene sequencing coupled to a genetic toolbox to rapidly synthesise TCR genes in the laboratory. Screening and characterisation of identified and synthesised TCRs is conducted using different forms of engineered TCR-presenting cells (eTPC) to carefully select therapeutic TCR candidates. Anocca’s unique genetic and cellular tools can also rapidly engineer TCR candidates to optimise their functionality.
TCRs can be deployed therapeutically via TCR-modified T-cell therapies. This cell therapy product is produced by purifying T-cells from a patient and equipping them with the selected TCRs specific for disease antigens, prior to reinfusion of the modified T-cells. Anocca has its own manufacturing facility approved by the Swedish authorities for the manufacture of cell therapy products.